Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
news

NICE recommends Lokelma treatment for hyperkalaemia

Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.

The UK National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Document (FAD) for Lokelma (sodium zirconium cyclosilicate [SZC]). The FAD recommends the drug as an option for treating hyperkalaemia in adults.

The drug, produced by AstraZeneca, was reported to have statistically significant and clinically meaningful improvement for patients in its Phase IIIb DIALIZE trial.

The treatment is an option for adults but only if used in emergency care for acute life-threatening hyperkalaemia alongside standard care or in outpatient care for people with persistent hyperkalaemia and chronic kidney disease stage 3b to 5 or heart failure, if they:

  • Have a confirmed serum potassium level of at least 6.0 mmol/litre
  • Are not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia
  • Are not on dialysis.

NICE recommended ceasing Lokelma administration in outpatient care if RAAS inhibitors are no longer a viable option.

“SZC provides a new treatment option for patients who develop high potassium levels,” said Professor David Wheeler, Honorary Consultant Nephrologist and Professor of Kidney Medicine at the Royal Free London NHS Foundation Trust. “It may allow long-term treatment for patients who develop recurrent high potassium levels, such as those with chronic kidney disease.”